These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 18513528)

  • 1. Plasma N-terminal protype-B natriuretic peptide levels in risk assessment of patients with mitral regurgitation secondary to ischemic and nonischemic dilated cardiomyopathy.
    Dini FL; Fontanive P; Conti U; Andreini D; Cabani E; De Tommasi SM
    Am Heart J; 2008 Jun; 155(6):1121-7. PubMed ID: 18513528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
    von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
    J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relation of N-terminal pro-B-type natriuretic peptide to symptoms, severity, and left ventricular remodeling in patients with organic mitral regurgitation.
    Potocki M; Mair J; Weber M; Hamm C; Burkard T; Hiemetzberger R; Peters K; Jander N; Cron TA; Hess N; Hoffmann A; Gekeler H; Gohlke-Bärwolf C; Buser P; Mueller C
    Am J Cardiol; 2009 Aug; 104(4):559-64. PubMed ID: 19660612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ventricular reverse remodeling early after mitral valve repair for severe chronic mitral regurgitation with atrial fibrillation.
    Song BG; On YK; Jeon ES; Park JH; Choi JO; Lee SC; Park SW; Kim JS; Park PW
    Cardiology; 2009; 114(2):132-41. PubMed ID: 19521078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) for left ventricular dysfunction in patients with chronic kidney disease stage 5 on haemodialysis.
    David S; Kümpers P; Seidler V; Biertz F; Haller H; Fliser D
    Nephrol Dial Transplant; 2008 Apr; 23(4):1370-7. PubMed ID: 18089624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-terminal pro-brain natriuretic peptide, kidney disease and outcome in patients with chronic heart failure.
    Bruch C; Reinecke H; Stypmann J; Rothenburger M; Schmid C; Breithardt G; Wichter T; Gradaus R
    J Heart Lung Transplant; 2006 Sep; 25(9):1135-41. PubMed ID: 16962477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction.
    Grewal J; McKelvie RS; Persson H; Tait P; Carlsson J; Swedberg K; Ostergren J; Lonn E
    Am J Cardiol; 2008 Sep; 102(6):733-7. PubMed ID: 18773998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic and prognostic value of N-terminal pro B-type natriuretic peptide (NT-proBNP) in patients with chronic aortic regurgitation.
    Weber M; Hausen M; Arnold R; Moellmann H; Nef H; Elsaesser A; Mitrovic V; Hamm C
    Int J Cardiol; 2008 Jul; 127(3):321-7. PubMed ID: 18055041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of NT-proBNP in the assessment of patients with aortic or mitral regurgitation.
    Petracca F; Affuso F; Di Conza P; Micillo F; Castellano G; Guardasole V; Scopacasa F; Saccà L; Fazio S
    J Cardiovasc Med (Hagerstown); 2009 Dec; 10(12):928-32. PubMed ID: 19606057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma N-terminal pro-brain natriuretic peptide: a marker of left ventricular hypertrophy in hypertrophic cardiomyopathy.
    Brito D; Matias JS; Sargento L; Cabral MJ; Madeira HC
    Rev Port Cardiol; 2004 Dec; 23(12):1557-82. PubMed ID: 15732658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aminoterminal B-type pro-natriuretic peptide as a marker of recovery after high-risk coronary artery bypass grafting in patients with ischemic heart disease and severe impaired left ventricular function.
    Rothenburger M; Stypmann J; Bruch C; Wichter T; Hoppe M; Drees G; Berendes E; Huelsken G; Loeher A; Welp H; Röttger C; Schmid C; Scheld HH; Tjan TD
    J Heart Lung Transplant; 2006 May; 25(5):596-602. PubMed ID: 16678040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Midregional pro-atrial natriuretic peptide is a useful indicator for the detection of impaired left ventricular function in patients with coronary artery disease.
    Elmas E; Brueckmann M; Lang S; Kälsch T; Haghi D; Sueselbeck T; Dempfle CE; Borggrefe M
    Int J Cardiol; 2008 Aug; 128(2):244-9. PubMed ID: 17673312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NT-proBNP levels in the evaluation of right ventricular dysfunction in patients with coronary artery disease and abnormal left ventricular wall motion: a magnetic resonance imaging study.
    Krittayaphong R; Boonyasirinant T; Saiviroonporn P; Udompunturak S
    Coron Artery Dis; 2008 Nov; 19(7):481-7. PubMed ID: 18923244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death.
    Moertl D; Berger R; Struck J; Gleiss A; Hammer A; Morgenthaler NG; Bergmann A; Huelsmann M; Pacher R
    J Am Coll Cardiol; 2009 May; 53(19):1783-90. PubMed ID: 19422985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutoff values of NT-proBNP for the prediction of low functional capacity, decreased ejection fraction and cardiovascular events in patients with heart failure.
    Koç M; Bozkurt A; Yildiray-Sahin D; Unal I; Acartürk E
    Cardiol J; 2009; 16(1):43-9. PubMed ID: 19130415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased plasma concentrations of N-terminal pro-B-type natriuretic peptide in patients with mild primary hyperparathyroidism.
    Almqvist EG; Becker C; Bondeson AG; Bondeson L; Svensson J; Svensson SE
    Clin Endocrinol (Oxf); 2006 Dec; 65(6):760-6. PubMed ID: 17121527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness and predictive value of circulating NT-proBNP levels to stratify patients for referral and priority treatment in a specialized outpatient heart failure center.
    Amir O; Paz H; Ammar R; Yaniv N; Schliamser JE; Lewis BS
    Isr Med Assoc J; 2008 Feb; 10(2):109-12. PubMed ID: 18432021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B-type natriuretic peptide in organic mitral regurgitation: determinants and impact on outcome.
    Detaint D; Messika-Zeitoun D; Avierinos JF; Scott C; Chen H; Burnett JC; Enriquez-Sarano M
    Circulation; 2005 May; 111(18):2391-7. PubMed ID: 15883225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of N-terminal pro-B-type natriuretic peptide in patients with acute coronary syndromes.
    Coppola G; Corrado E; Mulè MC; Augugliaro S; Cucchiara A; Novo G; Amoroso G; Assennato P; Hoffmann E; Vitale F; Novo S
    Coron Artery Dis; 2009 May; 20(3):225-9. PubMed ID: 19387249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The diagnostic utility of N-terminal pro-B-type natriuretic peptide for the detection of major structural heart disease in patients with atrial fibrillation.
    Shelton RJ; Clark AL; Goode K; Rigby AS; Cleland JG
    Eur Heart J; 2006 Oct; 27(19):2353-61. PubMed ID: 16952921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.